Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring high-molecular-weight glycosaminoglycan found in connective tissue, synovial fluid, and the eye. It functions as a lubricant, shock absorber, and moisturizing agent. It is available in various formulations, including intra-articular injections, ophthalmic solutions, and topical preparations.
## Primary Indications
* **Osteoarthritis (OA) of the knee:** Symptomatic relief in patients failing conservative therapy (intra-articular).
* **Ophthalmic surgery:** Viscoelastic aid in anterior segment surgery (e.g., cataract extraction).
* **Dry Eye Syndrome:** Ocular lubrication (topical).
* **Dermal fillers:** Soft tissue augmentation (aesthetic).
## Adult Dosing
* **Intra-articular (Knee OA):**
* *Sodium Hyaluronate (10 mg/mL):* 2 mL weekly for 3 weeks.
* *Hylan G-F 20:* 2 mL once weekly for 3 weeks OR a single 6 mL dose depending on product specific labeling.
* *Note:* Regimens vary significantly by manufacturer (e.g., Synvisc, Hyalgan, Euflexxa). Refer to the specific product label for the approved injection schedule.
* **Ophthalmic (Dry Eye):** Apply 0.1% to 0.4% solution to the affected eye(s) 1 to 4 times daily as needed.
## Pediatric Dosing
* **General:** Use is not established for knee OA in pediatric patients.
* **Ophthalmic:** Safety and efficacy for dry eye have not been rigorously established in pediatric populations; use follows provider discretion and conservative product labeling.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No adjustments typically required for local (intra-articular/topical/ophthalmic) administration.
* **Geriatric:** No specific dose adjustments required, but monitor for joint effusion or site reaction.
## Contraindications
* **Hypersensitivity:** Known hypersensitivity to hyaluronan preparations.
* **Avian/Egg Protein:** Certain Hylan G-F 20 products are derived from avian sources; contraindication exists for patients with known hypersensitivity to bird products (feathers, eggs, poultry).
* **Joint Infection:** Do not inject into a knee with active infection, skin disease, or inflammation at the injection site.
## Adverse Effects
* **Intra-articular:** Injection site pain, joint swelling/effusion, transient arthralgia, stiffness, and rare systemic hypersensitivity reactions.
* **Ophthalmic:** Transient blurred vision, mild stinging, or ocular irritation.
## Key Drug Interactions
* **Quaternary Ammonium Salts:** Do not use ocular solutions with quaternary ammonium compounds (e.g., benzalkonium chloride) as they may precipitate HA.
* **Disinfectants:** Do not use skin disinfectants containing quaternary ammonium salts for skin preparation prior to intra-articular injection.
## Monitoring
* **Intra-articular:** Monitor for post-injection flare (increased pain/swelling within 24–48 hours). Evaluate joint effusion; if present, consider aspiration.
* **Ophthalmic:** Monitor for persistent ocular irritation or vision changes.
## Clinical Pearls
* **Treatment Latency:** Intra-articular injections are not immediate analgesics; symptomatic benefit may take several weeks to manifest.
* **Viscosity:** Clinical efficacy in OA is thought to be mediated by the restoration of the viscoelastic properties of diseased synovial fluid.
* **Not Interchangeable:** Hyaluronic acid products are biologic molecules with varying molecular weights and sourcing; they are **not** interchangeable. Ensure the specific brand/formulation is verified.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by institution and country. Always verify current prescribing information, package inserts, and local clinical guidelines before prescribing or administering medication.
